Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 804.35 INR -2.03%
Market Cap: 144.1B INR

P/E
Price to Earnings

7.9
Current
14.9
Median
20.5
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
7.9
=
Market Cap
145.7B INR
/
Net Income
18.7B INR
Earnings Growth PEG
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average P/E: 25.8
7.9
-16%
N/A
US
Eli Lilly and Co
NYSE:LLY
73.5
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.9
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
20.8
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.4
16%
1.3
CH
Novartis AG
SIX:NOVN
18.9
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.6
29%
0.6

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
7.3
2-Years Forward
P/E
6.7
3-Years Forward
P/E
17.9